Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
0 (1y: -100%)
Market Cap 175.82 M P/E(ttm)
Enterprise Value 141.51 M P/B 7.81
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
Cash to Debt No Debt
SHP's Cash to Debt is ranked higher than
75% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SHP: No Debt )
SHP' s 10-Year Cash to Debt Range
Min: 11.19   Max: No Debt
Current: No Debt
Interest Coverage No Debt
SHP's Interest Coverage is ranked higher than
77% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SHP: No Debt )
SHP' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
F-Score: 5
M-Score: -2.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
Operating margin (%) 8.70
SHP's Operating margin (%) is ranked higher than
70% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -52.55 vs. SHP: 8.70 )
SHP' s 10-Year Operating margin (%) Range
Min: 8.7   Max: 16.3
Current: 8.7
8.7
16.3
Net-margin (%) 10
SHP's Net-margin (%) is ranked higher than
72% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -55.70 vs. SHP: 10 )
SHP' s 10-Year Net-margin (%) Range
Min: 10   Max: 15
Current: 10
10
15
ROE (%) 8.4
SHP's ROE (%) is ranked higher than
74% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -16.60 vs. SHP: 8.4 )
SHP' s 10-Year ROE (%) Range
Min: 8.4   Max: 90.5
Current: 8.4
8.4
90.5
ROA (%) 6.7
SHP's ROA (%) is ranked higher than
73% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -14.40 vs. SHP: 6.7 )
SHP' s 10-Year ROA (%) Range
Min: 6.7   Max: 14.7
Current: 6.7
6.7
14.7
ROC (Joel Greenblatt) (%) 4.80
SHP's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -0.20 vs. SHP: 4.80 )
SHP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 3.2   Max: 28.4
Current: 4.8
3.2
28.4
ยป SHP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

SHP Guru Trades in

Q3 2012

SHP Guru Trades in Q3 2012

Jim Simons 14,700 sh (New)
» More
Q4 2012

SHP Guru Trades in Q4 2012

Jim Simons 26,224 sh (+78.39%)
» More
Q1 2013

SHP Guru Trades in Q1 2013

Jim Simons 73,646 sh (+180.83%)
» More
» Details

Insider Trades

Latest Guru Trades with SHP



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/B 7.81
SHP's P/B is ranked higher than
86% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. SHP: 7.81 )
SHP' s 10-Year P/B Range
Min: 0.8   Max: 2.02
Current: 7.81
0.8
2.02
P/S 1.33
SHP's P/S is ranked higher than
89% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 6.90 vs. SHP: 1.33 )
SHP' s 10-Year P/S Range
Min: 0.91   Max: 2.66
Current: 1.33
0.91
2.66
EV-to-EBIT 24.1
SHP's EV-to-EBIT is ranked lower than
53% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 14.61 vs. SHP: 24.1 )
SHP' s 10-Year EV-to-EBIT Range
Min: 42.5   Max: 148.5
Current: 24.1
42.5
148.5

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 33.1
SHP's Price/Net Cash is ranked lower than
64% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.80 vs. SHP: 33.1 )
SHP' s 10-Year Price/Net Cash Range
Min: 8   Max: 34.6
Current: 33.1
8
34.6
Price/Net Current Asset Value 5.8
SHP's Price/Net Current Asset Value is ranked lower than
58% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 32.60 vs. SHP: 5.8 )
SHP' s 10-Year Price/Net Current Asset Value Range
Min: 5.6   Max: 14.2
Current: 5.8
5.6
14.2
Price/Tangible Book 1.1
SHP's Price/Tangible Book is ranked lower than
65% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. SHP: 1.1 )
SHP' s 10-Year Price/Tangible Book Range
Min: 1   Max: 1.9
Current: 1.1
1
1.9
Price/Median PS Value 0.7
SHP's Price/Median PS Value is ranked lower than
66% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. SHP: 0.7 )
SHP' s 10-Year Price/Median PS Value Range
Min: 0.6   Max: 1.5
Current: 0.7
0.6
1.5

Business Description

ShangPharma Corporation is a pharmaceutical and biotechnology research and development outsourcing company providing integrated services across the drug discovery and development process to international and Chinese pharmaceutical and biotechnology companies. Its services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. Discovery chemistry consists of medicinal chemistry, synthetic chemistry and analytical chemistry. Discovery biology and preclinical development consists of assay development and high throughput screening, pharmacology and reagent generation. Pharmaceutical development consists of preformulation and formulation, process R&D, analytical development and research manufacturing. Biologics consists of therapeutic antibody generation, antibody optimizing and engineering, and analytical services for large molecules. ShangPharma Corporation is headquartered in Shanghai, the People's Republic
Company Website
Industry: Biotechnology
Compare:

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial